COVID-19候选疫苗-话题@MedSci

#COVID-19候选疫苗#

19篇内容 | 1085人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1562058, encodeId=d36f15620589b, content=<a href='/topic/show?id=6875513376' target=_blank style='color:#2F92EE;'>#COVID-19候选疫苗#</a>, objectTitle=防御南非变种！Moderna的变异特异性COVID-19候选疫苗即将进入临床阶段, objectType=article, longId=207592, objectId=d9be20e59233, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d9be20e59233, replyNumber=0, likeNumber=94, createdTime=2021-02-27, rootId=0, userName=piaojinhua, userId=077d15252580, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d9be20e59233, moduleTitle=防御南非变种！Moderna的变异特异性COVID-19候选疫苗即将进入临床阶段, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d9be20e59233)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1562057, encodeId=9c4b156205e0a, content=<a href='/topic/show?id=6875513376' target=_blank style='color:#2F92EE;'>#COVID-19候选疫苗#</a>, objectTitle=COVID-19候选疫苗VLA2001已完成I / II期临床试验的患者招募, objectType=article, longId=206516, objectId=fdf420651685, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fdf420651685, replyNumber=0, likeNumber=64, createdTime=2021-02-02, rootId=0, userName=piaojinhua, userId=077d15252580, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fdf420651685, moduleTitle=COVID-19候选疫苗VLA2001已完成I / II期临床试验的患者招募, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fdf420651685)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1562056, encodeId=28031562056dc, content=<a href='/topic/show?id=6875513376' target=_blank style='color:#2F92EE;'>#COVID-19候选疫苗#</a>, objectTitle=COVID-19候选疫苗SN14将进入临床试验, objectType=article, longId=204716, objectId=42a1204e16be, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=42a1204e16be, replyNumber=0, likeNumber=71, createdTime=2020-12-22, rootId=0, userName=piaojinhua, userId=077d15252580, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=42a1204e16be, moduleTitle=COVID-19候选疫苗SN14将进入临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=42a1204e16be)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1562055, encodeId=bd9515620557f, content=<a href='/topic/show?id=6875513376' target=_blank style='color:#2F92EE;'>#COVID-19候选疫苗#</a>, objectTitle=新加坡COVID-19候选疫苗（ARCT-021）表现良好，或将于2021年第一季度交付使用, objectType=article, longId=203836, objectId=cae620383623, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cae620383623, replyNumber=0, likeNumber=76, createdTime=2020-11-30, rootId=0, userName=piaojinhua, userId=077d15252580, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cae620383623, moduleTitle=新加坡COVID-19候选疫苗（ARCT-021）表现良好，或将于2021年第一季度交付使用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cae620383623)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1562054, encodeId=59c31562054d4, content=<a href='/topic/show?id=6875513376' target=_blank style='color:#2F92EE;'>#COVID-19候选疫苗#</a>, objectTitle=阿斯利康的COVID-19候选疫苗：有效率达70％, objectType=article, longId=203678, objectId=d9f82036e8c7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d9f82036e8c7, replyNumber=0, likeNumber=69, createdTime=2020-11-25, rootId=0, userName=piaojinhua, userId=077d15252580, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d9f82036e8c7, moduleTitle=阿斯利康的COVID-19候选疫苗：有效率达70％, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d9f82036e8c7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1562053, encodeId=ba2f1562053c7, content=<a href='/topic/show?id=6875513376' target=_blank style='color:#2F92EE;'>#COVID-19候选疫苗#</a>, objectTitle=Novavax已在英国开始COVID-19候选疫苗NVX-CoV2373的III期临床试验, objectType=article, longId=201324, objectId=3539201324d6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3539201324d6, replyNumber=0, likeNumber=61, createdTime=2020-09-30, rootId=0, userName=piaojinhua, userId=077d15252580, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3539201324d6, moduleTitle=Novavax已在英国开始COVID-19候选疫苗NVX-CoV2373的III期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3539201324d6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1562052, encodeId=b9961562052ba, content=<a href='/topic/show?id=6875513376' target=_blank style='color:#2F92EE;'>#COVID-19候选疫苗#</a>, objectTitle=COVID-19候选疫苗LUNAR®-COV19（ARCT-021）：临床前研究确认了有效性, objectType=article, longId=200319, objectId=d68c20031934, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d68c20031934, replyNumber=0, likeNumber=70, createdTime=2020-09-07, rootId=0, userName=piaojinhua, userId=077d15252580, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d68c20031934, moduleTitle=COVID-19候选疫苗LUNAR®-COV19（ARCT-021）：临床前研究确认了有效性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d68c20031934)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1562050, encodeId=84b7156205010, content=<a href='/topic/show?id=6875513376' target=_blank style='color:#2F92EE;'>#COVID-19候选疫苗#</a>, objectTitle=强生旗下COVID-19候选疫苗Ad26.COV2.S：即将开展I/IIa期临床研究, objectType=article, longId=198422, objectId=d19d19842276, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d19d19842276, replyNumber=0, likeNumber=79, createdTime=2020-08-01, rootId=0, userName=piaojinhua, userId=077d15252580, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d19d19842276, moduleTitle=强生旗下COVID-19候选疫苗Ad26.COV2.S：即将开展I/IIa期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d19d19842276)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1562049, encodeId=511815620491f, content=<a href='/topic/show?id=6875513376' target=_blank style='color:#2F92EE;'>#COVID-19候选疫苗#</a>, objectTitle=NEJM：COVID-19候选疫苗mRNA-1273的临床前研究，效果明显！, objectType=article, longId=198318, objectId=b1ae19831868, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b1ae19831868, replyNumber=0, likeNumber=63, createdTime=2020-07-31, rootId=0, userName=piaojinhua, userId=077d15252580, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b1ae19831868, moduleTitle=NEJM：COVID-19候选疫苗mRNA-1273的临床前研究，效果明显！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b1ae19831868)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1562051, encodeId=422715620513d, content=<a href='/topic/show?id=6875513376' target=_blank style='color:#2F92EE;'>#COVID-19候选疫苗#</a>, objectTitle=CDMO或可加速COVID-19候选疫苗的大规模生产, objectType=article, longId=198198, objectId=d29019819849, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d29019819849, replyNumber=0, likeNumber=75, createdTime=2020-07-30, rootId=0, userName=piaojinhua, userId=077d15252580, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d29019819849, moduleTitle=CDMO或可加速COVID-19候选疫苗的大规模生产, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d29019819849)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1562048, encodeId=a4c115620487a, content=<a href='/topic/show?id=6875513376' target=_blank style='color:#2F92EE;'>#COVID-19候选疫苗#</a>, objectTitle=COVID-19候选疫苗mRNA-1273的III临床试验：规模将继续扩大, objectType=article, longId=198171, objectId=c8e91981e1ab, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c8e91981e1ab, replyNumber=0, likeNumber=72, createdTime=2020-07-29, rootId=0, userName=piaojinhua, userId=077d15252580, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c8e91981e1ab, moduleTitle=COVID-19候选疫苗mRNA-1273的III临床试验：规模将继续扩大, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c8e91981e1ab)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1562047, encodeId=ca7a156204eff, content=<a href='/topic/show?id=6875513376' target=_blank style='color:#2F92EE;'>#COVID-19候选疫苗#</a>, objectTitle=NEJM：Moderna的COVID-19候选疫苗在所有受试者中诱导了强烈的免疫应答, objectType=article, longId=197569, objectId=a86319e569b8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a86319e569b8, replyNumber=0, likeNumber=118, createdTime=2020-07-17, rootId=0, userName=piaojinhua, userId=077d15252580, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a86319e569b8, moduleTitle=NEJM：Moderna的COVID-19候选疫苗在所有受试者中诱导了强烈的免疫应答, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a86319e569b8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1562046, encodeId=6136156204632, content=<a href='/topic/show?id=6875513376' target=_blank style='color:#2F92EE;'>#COVID-19候选疫苗#</a>, objectTitle=COVID-19候选疫苗SCB-2019进展顺利, objectType=article, longId=196290, objectId=1ce1196290e4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1ce1196290e4, replyNumber=0, likeNumber=0, createdTime=2020-06-24, rootId=0, userName=piaojinhua, userId=077d15252580, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1ce1196290e4, moduleTitle=COVID-19候选疫苗SCB-2019进展顺利, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1ce1196290e4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1562045, encodeId=e0f5156204524, content=<a href='/topic/show?id=6875513376' target=_blank style='color:#2F92EE;'>#COVID-19候选疫苗#</a>, objectTitle=Novavax启动COVID-19候选疫苗NVX-CoV2373的I / II期试验, objectType=article, longId=194739, objectId=c5e8194e39ed, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c5e8194e39ed, replyNumber=0, likeNumber=71, createdTime=2020-05-28, rootId=0, userName=piaojinhua, userId=077d15252580, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c5e8194e39ed, moduleTitle=Novavax启动COVID-19候选疫苗NVX-CoV2373的I / II期试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c5e8194e39ed)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1562044, encodeId=f8fa156204430, content=<a href='/topic/show?id=6875513376' target=_blank style='color:#2F92EE;'>#COVID-19候选疫苗#</a>, objectTitle=CureVac的COVID-19候选疫苗可触发免疫反应, objectType=article, longId=194238, objectId=482b194238a0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=482b194238a0, replyNumber=0, likeNumber=63, createdTime=2020-05-17, rootId=0, userName=piaojinhua, userId=077d15252580, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=482b194238a0, moduleTitle=CureVac的COVID-19候选疫苗可触发免疫反应, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=482b194238a0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1562043, encodeId=e8981562043b4, content=<a href='/topic/show?id=6875513376' target=_blank style='color:#2F92EE;'>#COVID-19候选疫苗#</a>, objectTitle=bioRxiv：一种COVID-19候选疫苗在恒河猴体内试验成功了!, objectType=article, longId=192896, objectId=b3881928967f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b3881928967f, replyNumber=0, likeNumber=72, createdTime=2020-04-26, rootId=0, userName=piaojinhua, userId=077d15252580, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b3881928967f, moduleTitle=bioRxiv：一种COVID-19候选疫苗在恒河猴体内试验成功了!, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b3881928967f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1562042, encodeId=3e091562042ee, content=<a href='/topic/show?id=6875513376' target=_blank style='color:#2F92EE;'>#COVID-19候选疫苗#</a>, objectTitle=COVID-19候选疫苗（PittCoVacc，匹兹堡冠状病毒疫苗）：动物实验显成效, objectType=article, longId=191370, objectId=03ee1913e086, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=03ee1913e086, replyNumber=0, likeNumber=79, createdTime=2020-04-05, rootId=0, userName=piaojinhua, userId=077d15252580, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=03ee1913e086, moduleTitle=COVID-19候选疫苗（PittCoVacc，匹兹堡冠状病毒疫苗）：动物实验显成效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=03ee1913e086)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1562041, encodeId=f697156204133, content=<a href='/topic/show?id=6875513376' target=_blank style='color:#2F92EE;'>#COVID-19候选疫苗#</a>, objectTitle=强生表示，针对新冠COVID-19候选疫苗的临床试验最迟于9月开始，预计2021年初正式上市使用, objectType=article, longId=191234, objectId=1a0e1912345a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1a0e1912345a, replyNumber=0, likeNumber=76, createdTime=2020-04-03, rootId=0, userName=heli0118, userId=21015, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1a0e1912345a, moduleTitle=强生表示，针对新冠COVID-19候选疫苗的临床试验最迟于9月开始，预计2021年初正式上市使用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1a0e1912345a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1562040, encodeId=011915620409f, content=<a href='/topic/show?id=6875513376' target=_blank style='color:#2F92EE;'>#COVID-19候选疫苗#</a>, objectTitle=英国COVID-19候选疫苗ChAdOx1：将于下个月开始临床试验, objectType=article, longId=190564, objectId=50ab190564bf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=50ab190564bf, replyNumber=0, likeNumber=81, createdTime=2020-03-23, rootId=0, userName=piaojinhua, userId=077d15252580, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=50ab190564bf, moduleTitle=英国COVID-19候选疫苗ChAdOx1：将于下个月开始临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=50ab190564bf)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

COVID-19候选疫苗

2020-05-29

piaojinhua (审核中...)

前往app查看评论内容

#COVID-19候选疫苗#

防御南非变种！Moderna的变异特异性COVID-19候选疫苗即将进入临床阶段

2021-02-27

piaojinhua (审核中...)

前往app查看评论内容

#COVID-19候选疫苗#

COVID-19候选疫苗VLA2001已完成I / II期临床试验的患者招募

2021-02-02

piaojinhua (审核中...)

前往app查看评论内容

#COVID-19候选疫苗#

COVID-19候选疫苗SN14将进入临床试验

2020-12-22

piaojinhua (审核中...)

前往app查看评论内容

#COVID-19候选疫苗#

新加坡COVID-19候选疫苗（ARCT-021）表现良好，或将于2021年第一季度交付使用

2020-11-30

piaojinhua (审核中...)

前往app查看评论内容

#COVID-19候选疫苗#

阿斯利康的COVID-19候选疫苗：有效率达70％

2020-11-25

piaojinhua (审核中...)

前往app查看评论内容

#COVID-19候选疫苗#

Novavax已在英国开始COVID-19候选疫苗NVX-CoV2373的III期临床试验

2020-09-30

piaojinhua (审核中...)

前往app查看评论内容

#COVID-19候选疫苗#

COVID-19候选疫苗LUNAR®-COV19（ARCT-021）：临床前研究确认了有效性

2020-09-07

piaojinhua (审核中...)

前往app查看评论内容

#COVID-19候选疫苗#

强生旗下COVID-19候选疫苗Ad26.COV2.S：即将开展I/IIa期临床研究

2020-08-01

piaojinhua (审核中...)

前往app查看评论内容

#COVID-19候选疫苗#

NEJM：COVID-19候选疫苗mRNA-1273的临床前研究，效果明显！

2020-07-31

piaojinhua (审核中...)

前往app查看评论内容

#COVID-19候选疫苗#

CDMO或可加速COVID-19候选疫苗的大规模生产

2020-07-30

piaojinhua (审核中...)

前往app查看评论内容

#COVID-19候选疫苗#

COVID-19候选疫苗mRNA-1273的III临床试验：规模将继续扩大

2020-07-29

piaojinhua (审核中...)

前往app查看评论内容

#COVID-19候选疫苗#

NEJM：Moderna的COVID-19候选疫苗在所有受试者中诱导了强烈的免疫应答

2020-07-17

piaojinhua (审核中...)

前往app查看评论内容

#COVID-19候选疫苗#

COVID-19候选疫苗SCB-2019进展顺利

2020-06-24

piaojinhua (审核中...)

前往app查看评论内容

#COVID-19候选疫苗#

Novavax启动COVID-19候选疫苗NVX-CoV2373的I / II期试验

2020-05-28

piaojinhua (审核中...)

前往app查看评论内容

#COVID-19候选疫苗#

CureVac的COVID-19候选疫苗可触发免疫反应

2020-05-17

piaojinhua (审核中...)

前往app查看评论内容

#COVID-19候选疫苗#

bioRxiv：一种COVID-19候选疫苗在恒河猴体内试验成功了!

2020-04-26

piaojinhua (审核中...)

前往app查看评论内容

#COVID-19候选疫苗#

COVID-19候选疫苗（PittCoVacc，匹兹堡冠状病毒疫苗）：动物实验显成效

2020-04-05

heli0118 (审核中...)

前往app查看评论内容

#COVID-19候选疫苗#

强生表示，针对新冠COVID-19候选疫苗的临床试验最迟于9月开始，预计2021年初正式上市使用

2020-04-03

piaojinhua (审核中...)

前往app查看评论内容

#COVID-19候选疫苗#

英国COVID-19候选疫苗ChAdOx1：将于下个月开始临床试验

2020-03-23

科室
- - 订阅+
  - 更多科室
工具
服务